Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 12, Number 10—October 2006

Research

Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children

Lisa A. Prosser*†Comments to Author , Carolyn Buxton Bridges‡, Timothy M. Uyeki‡, Virginia L. Hinrichsen*†, Martin I. Meltzer‡, Noelle-Angelique M. Molinari‡, Benjamin Schwartz‡, William W. Thompson‡, Keiji Fukuda‡, and Tracy A. Lieu*†§
Author affiliations: *Harvard Medical School, Boston, Massachusetts, USA; †Harvard Pilgrim Health Care, Boston, Massachusetts, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA; §Children's Hospital, Boston, Massachusetts, USA

Main Article

Figure 2

Cost-effectiveness acceptability curves for inactivated influenza vaccine compared with no vaccination (A, children not a high risk; B, children at high risk). Cost-effective acceptability curves for live, attenuated vaccine compared with no vaccine (C, children not at high risk only). Box indicates the mean cost-effectiveness ratio.

Figure 2. Cost-effectiveness acceptability curves for inactivated influenza vaccine compared with no vaccination (A, children not a high risk; B, children at high risk). Cost-effective acceptability curves for live, attenuated vaccine compared with no vaccine (C, children not at high risk only). Box indicates the mean cost-effectiveness ratio.

Main Article

TOP